Status:
RECRUITING
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer. The ...
Detailed Description
ACE is expressed in triple-negative breast cancer cells. This project develops new type of 68GA-labeled DOTA-BPP, leveraging the inherent strengths of this nuclear medicine discipline, promoted the fo...
Eligibility Criteria
Inclusion
- 18-75 years old;
- ECOG score 0 or 1 point;
- Participants with confirmed TNBC cancer who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
Exclusion
- Pregnant or nursing;
- Severe hepatic or renal dysfunction;
- Low WBC (less than 3 x 10\^9/L);
- Unable to comply with the PET/CT imaging procedures
Key Trial Info
Start Date :
October 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06203119
Start Date
October 1 2022
End Date
October 1 2024
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ethics Committee of Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142